The 2024 Annual Report of BMS outlines the company’s financial results and activities over the past year. BMS recorded a 15% growth in revenue compared to the previous year, reaching $2 billion, due to the market recovery post-pandemic. The earnings per share (EPS) also rose to $3.5, reflecting high business efficiency. Key sectors such as pharmaceuticals, healthcare, and biotechnology continue to contribute the most to revenue. Additionally, BMS has heavily invested in research and development, with expenditures reaching $500 million for new projects, especially in cancer treatment and rare diseases. Two new products launched successfully in 2024 received positive consumer feedback. The company also focuses on sustainability and social responsibility, committing to achieve net carbon emissions by 2030. BMS calls on shareholders to continue supporting its path of sustainable development and innovation.
Leave a Reply